Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Nextkidney Sg Pte. Ltd. has 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This involves 1 distinct examiner and 1 distinct art unit. ROBINSON, HOPE A is the busiest examiner, with 1 busiest examiner pending action. The current prosecution activity is concentrated under 1 distinct examiner and within 1 distinct art unit.
This concentration in the Biotechnology & Pharmaceuticals sector indicates a narrow technical focus for the company's current 1 pending office action. Having 1 distinct examiner, ROBINSON, HOPE A, allows for a consistent and targeted prosecution approach. The 1 pending office action represents the total active workload for this entity at the moment. With only 1 distinct art unit involved, the subject matter is likely confined to a specific technical classification. The fact that ROBINSON, HOPE A holds 1 busiest examiner pending action confirms that there are no other examiners currently reviewing pending actions for the company. This streamlined profile makes it easier to manage the prosecution process.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| ROBINSON, HOPE A | 1 | 67.7% | +43.0% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18548909 | Stable storage of enzymes | ROBINSON, HOPE A | 39d |
| Art Unit | Apps |
|---|---|
| 1652 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18548909 | Stable storage of enzymes | ROBINSON, HOPE A | 1652 | §103 | Final Rejection | 39d | Pending | Sep 04, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialNextkidney Sg Pte. Ltd. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Hope A Robinson has the most, with 1 of Nextkidney Sg Pte. Ltd.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
